-+ 0.00%
-+ 0.00%
-+ 0.00%
Johnson & Johnson makes $465 million equity investment in Sail Biomedicines
Share
Listen to the news
Johnson & Johnson makes $465 million equity investment in Sail Biomedicines
  • Johnson & Johnson agreed to invest USD 465 million in Sail Biomedicines through an equity investment.
  • Total initial payments set at USD 785 million, tied to a collaboration on in vivo CAR-T programs for immune-mediated diseases.
  • Deal includes up to USD 140 million in contingent payments if development milestones are met.
  • Johnson & Johnson also secured an exclusive option to acquire Sail for USD 2.58 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via Business Wire (Ref. ID: 20260729687815) on July 29, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending